Triptorelin Market Analysis

With respect to application, cancer segment accounted for more than 25% of the overall triptorelin industry share in 2022, on account of growing prevalence of cancer across the globe. As per WHO, cancer is the leading cause of death around the world and was responsible for nearly 10 million deaths in 2020. Prostate cancer, especially, is pegged to lead the charge by notably elevating the demand for triptorelin-based drugs. According to recent estimates from the American Cancer Society, the US is likely to record over 288,300 new cases of prostate cancer in 2023 alone.
 

Based on the route of administration, triptorelin market share from intradermal segment is likely to grow at over 4.5% CAGR from 2023 to 2032, fueled by the growing number of hormone therapies performed annually across the globe. Intradermal injections are widely utilized in such therapeutic procedures, which fosters the segment demand. They can also be used in TB tests, sensitivity tests for allergies, local anesthetic, and others. Intradermal delivery of vaccines is more efficient than injection into the subcutaneous tissue or muscle and reduces the antigen volume.
 

Europe triptorelin market is anticipated to reach a valuation of more than USD 370 million by 2032, owing to numerous industry players focusing on expanding their footprint across several European countries. Meanwhile, Europe is also increasingly investing on the health and well-being of its citizens to effectively address the increasing occurrence of endometriosis, cancer in the region. In fact, the region reports over 1.9 million deaths and 3.7 million new cases of cancer annually, making the disease its second leading cause of death and morbidity. In addition, rising disposable income has proliferated the demand for triptorelin-based drugs by bringing them in reach of more customers.